Cite
Blake SJ, James J, Ryan FJ, et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep Med. 2021;2(12):100464doi: 10.1016/j.xcrm.2021.100464.
Blake, S. J., James, J., Ryan, F. J., Caparros-Martin, J., Eden, G. L., Tee, Y. C., Salamon, J. R., Benson, S. C., Tumes, D. J., Sribnaia, A., Stevens, N. E., Finnie, J. W., Kobayashi, H., White, D. L., Wesselingh, S. L., O'Gara, F., Lynn, M. A., & Lynn, D. J. (2021). The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell reports. Medicine, 2(12), 100464. https://doi.org/10.1016/j.xcrm.2021.100464
Blake, Stephen J, et al. "The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota." Cell reports. Medicine vol. 2,12 (2021): 100464. doi: https://doi.org/10.1016/j.xcrm.2021.100464
Blake SJ, James J, Ryan FJ, Caparros-Martin J, Eden GL, Tee YC, Salamon JR, Benson SC, Tumes DJ, Sribnaia A, Stevens NE, Finnie JW, Kobayashi H, White DL, Wesselingh SL, O'Gara F, Lynn MA, Lynn DJ. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep Med. 2021 Dec 08;2(12):100464. doi: 10.1016/j.xcrm.2021.100464. eCollection 2021 Dec 21. PMID: 35028606; PMCID: PMC8714857.
Copy
Download .nbib